Danaher Corp (NYSE: DHR) on Tuesday, plunged -0.70% from the previous trading day, before settling in for the closing price of $235.99. Within the past 52 weeks, DHR’s price has moved between $171.00 and $258.23.
A company in the Healthcare sector has jumped its sales by 9.03% annually for the last half of the decade. The company achieved an average annual earnings per share of 3.31%. With a float of $643.61 million, this company’s outstanding shares have now reached $706.30 million.
Danaher Corp (DHR) Insider Updates
Observing investor behavior towards Diagnostics & Research industry stocks is more important than anything else. The insider ownership of Danaher Corp is 8.88%, while institutional ownership is 82.30%. The most recent insider transaction that took place on Nov 25 ’25, was worth 9,359,067. In this transaction Chairman of Exec. Committee of this company sold 40,625 shares at a rate of $230.38, taking the stock ownership to the 850,000 shares. Before that another transaction happened on Nov 25 ’25, when Company’s insider proposed sale 40,625 for $226.98, making the entire transaction worth $9,221,063.
Danaher Corp (DHR) Performance Highlights and Predictions
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported 2.14 earnings per share (EPS) for the period falling under the consensus outlook (set at 2.16) by -0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 3.31% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.39% during the next five years compared to 9.03% growth over the previous five years of trading.
Danaher Corp (NYSE: DHR) Trading Performance Indicators
Danaher Corp (DHR) is currently performing well based on its current performance indicators. A quick ratio of 1.10 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.82. Likewise, its price to free cash flow for the trailing twelve months is 32.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 4.86, a number that is poised to hit 2.16 in the next quarter and is forecasted to reach 8.42 in one year’s time.
